GILD vs. JAZZ: Gilead Sciences vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

Gilead Sciences (GILD) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 5.05%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 4.37%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Gilead Sciences (GILD) at 1,684.21% delivers above-range EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% falls into the bottom quartile — a wide split in earnings momentum.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Jazz Pharmaceuticals (JAZZ) trades at 69.46 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Jazz Pharmaceuticals (JAZZ) at 3.59 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

Valuation Metrics